Thompson CA, Yost K, Larson MC, et al. Changes in Quality of Life in Indolent Non-Hodgkin Lymphoma 3 Years after Diagnosis. ASH 59th Annual Meeting & Exhibition, abstract 917.
Ublituximab plus ibrutinib versus ibrutinib alleen bij gerecidiveerde of refractaire hoogrisico CLL
mrt 2021 | Leukemie